Mediport use as an acceptable standard for CAR T cell infusion
Eylon M, Prabhu S, John S, King M, Bhatt D, Curran K, Erickson C, Karras N, Phillips C, Satwani P, Hermiston M, Southworth E, Baumeister S, Talano J, MacMillan M, Rossoff J, Bonifant C, Myers G, Rouce R, Toner K, Driscoll T, Katsanis E, Salzberg D, Schiff D, De Oliveira S, Capitini C, Pacenta H, Pfeiffer T, Shah N, Huynh V, Skiles J, Fraint E, McNerney K, Quigg T, Krueger J, Ligon J, Fabrizio V, Baggott C, Laetsch T, Schultz L. Mediport use as an acceptable standard for CAR T cell infusion. Frontiers In Immunology 2023, 14: 1239132. PMID: 37965315, PMCID: PMC10642031, DOI: 10.3389/fimmu.2023.1239132.Peer-Reviewed Original ResearchCAR T-cell infusionT-cell infusionCell infusionT-cell therapyCell infiltrationClinical practiceChimeric antigen receptor T-cell therapyCAR T-cell therapyCAR-T cell infiltrationCell therapyCell therapy administrationRetrospective cohort studyCentral venous cathetersT cell infiltrationCurrent clinical practiceStandard clinical practiceB-cell malignanciesT cell deliveryEvaluable patientsVenous optionsCohort studyVenous cathetersTherapy administrationPractice patternsCare recommendationsRole of abatacept in the prevention of graft-versus-host disease: current perspectives
Ngwube A, Rangarajan H, Shah N. Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Therapeutic Advances In Hematology 2023, 14: 20406207231152644. PMID: 36845849, PMCID: PMC9943961, DOI: 10.1177/20406207231152644.Peer-Reviewed Original ResearchHematopoietic stem cell transplantAllogeneic hematopoietic stem cell transplantChronic GVHDGVHD prophylaxisDonor hematopoietic stem cell transplantSteroid-refractory chronic GVHDPrevention of graftSevere acute GVHDStem cell transplantAcute GVHDGVHD preventionHLA disparityHost diseaseGraft rejectionHSCT settingUnrelated donorsCalcineurin inhibitorsCell transplantNonmalignant disordersAlternative donorsMouse modelClinical practiceGVHDProphylaxisLimited reports